跳至主要内容
临床试验/PACTR202105618971235
PACTR202105618971235已完成2 期

Clinical validation of a CYP2B6 pharmacogenetics test and dosing algorithm in the safe and efficacious use of Efavirenz and its cost effective & benefit analysis in a public healthcare setting

未提供0 个研究点目标入组 260 人开始时间: 2021年4月27日最近更新:

试验速览

阶段
2 期
状态
已完成
入组人数
260

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
All

入选标准

  • 1. HIV infected adults between 18 and 50 years
  • 2. CD4 T-cell counts between 50-500 cells per ul
  • 3. No previous AIDS defining illness
  • 4. Plasma HIV-1 RNA of at least 1000 copies per ml
  • 5. No short course for preventing mother to child transmission
  • 6. No previous exposure to antiretroviral therapy

排除标准

  • 1. Pregnancy or nursing mothers
  • 2. Had uncontrolled active opportunistic or malignant disease
  • 3. Present or recent use of prohibited or elicit medications adversely affecting participation
  • 4. Laboratory values outside predefined ranges -
  • i. Absolute neutrophil count <500 celss per ul
  • ii. Haemoglobin <7.0 g/dl
  • iii. Platelet count <50 000 cells per ul
  • iv. Aspartate aminotransferase, or alanine aminotransferase, or both >5 times the upper limit normal

研究者

发起方
未提供

相似试验